ArticleJTO clinical and research reports2022

A Phase 2 Clinical Trial of Combination Nivolumab, Ipilimumab, and Paclitaxel in Patients With Untreated Metastatic NSCLC: The OPTIMAL Trial.

Jeffrey M Clarke et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.